Dendritic cells: On the move from bench to bedside.
As dendritic cells increasingly become the adjuvant of choice in new approaches to cancer immunotherapy, a degree of protocol standardization is required to aid future large-scale clinical trials.
Nestle
F O
FO
Department of Dermatology, University of Zürich Medical School, Zürich, Switzerland.
Banchereau
J
J
Hart
D
D
D019496:Cancer Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002454:Cell Differentiation; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D011786:Quality Control
D019496:Cancer Vaccines